NasdaqGM:TNDMMedical Equipment
Can Tandem Diabetes Care (TNDM) Turn Revenue Beats Into Durable Returns On Capital?
Earlier this year, Tandem Diabetes Care reported Q1 revenue of US$247.2 million, up 5.5% year on year and ahead of analyst expectations, while also beating earnings estimates and reaffirming full-year revenue guidance.
Despite these operational gains, the results also drew attention to Tandem’s continuing lack of profitability and weakening returns on capital, raising questions about how effectively past growth investments are paying off.
We’ll now examine how Tandem’s strong Q1 revenue beat...